Michael Smylie

36.9k citations
92 papers · 9.2k · 3 hit papers · h-index 30

Impact in

  • Oncology top 0.2%
    • Cancer Immunotherapy and Biomarkers
    • Lung Cancer Research Studies
    • CAR-T cell therapy research
    • Colorectal Cancer Treatments and Studies
    • HER2/EGFR in Cancer Research
    • Lung Cancer Treatments and Mutations

Papers in

    • Cancer Immunotherapy and Biomarkers 36
    • CAR-T cell therapy research 32
    • Lung Cancer Research Studies 12
    • Cancer Treatment and Pharmacology 11
    • Cutaneous Melanoma Detection and Management 10
    • Melanoma and MAPK Pathways 19

Michael Smylie

88 papers receiving 9.0k citations

Michael Smylie's Hit Papers

Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial 2018 · 1.0k citations
1.0k0+7+14Years since publication10002.0k3.0k4.0k

Peers

Michael Smylie
Comparison fields: 5 of 108
  • Oncology 5.5k
  • Pulmonary and Respiratory Medicine 3.5k
  • Immunology 1.3k
  • Cancer Research 755
  • Molecular Biology 1.9k
Replace Daniil Stroyakovskiy with:
Daniil Stroyakovskiy Russia
Emiliano Calvo Spain
Laura Q.M. Chow United States
Theodore F. Logan United States
Craig Devoe United States
Jonathan E. Rosenberg United States
Elizabeth R. Plimack United States
Scott Gettinger United States
Delvys Rodríguez‐Abreu Spain
Shumei Kato United States
Michael Smylie relative to Daniil Stroyakovskiy Russia Daniil Stroyakovskiy's profile →
Citations per field
00.5×1.6×
Daniil Stroyakovskiy · 1×
Citations per year

Countries citing papers authored by Michael Smylie

Since Specialization
Citations

This map shows the geographic impact of Michael Smylie's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Smylie with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Smylie more than expected).

Fields of papers citing papers by Michael Smylie

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Smylie. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Smylie. The network helps show where Michael Smylie may publish in the future.

Co-authors

The 25 scholars most cited alongside Michael Smylie, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Michael Smylie Line = papers co-authored together Michael Smylie links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 92 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Hit paper breakdown →
20054289
2
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
Hit paper breakdown →
20181033
3
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
Hit paper breakdown →
2009939
4 2019253
5 2004202
6 2002192
7 2007156
8 2019124
9 2018111
10 2021103
11 2010101
12 201297
13 200191
14 200589
15 201582
16 201480
17 201167
18 202063
19 201663
20 201457

About Michael Smylie

Michael Smylie is a scholar working on Oncology, Molecular Biology, Immunology, Pulmonary and Respiratory Medicine and Cancer Research, having authored 92 papers that have together received 9.2k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (36 papers), CAR-T cell therapy research (32 papers), Melanoma and MAPK Pathways (19 papers), Immunotherapy and Immune Responses (14 papers), Lung Cancer Research Studies (12 papers), Cancer Treatment and Pharmacology (11 papers), Cutaneous Melanoma Detection and Management (10 papers) and Breast Cancer Treatment Studies (6 papers). The work is most often cited by research in Oncology (5.5k citations), Pulmonary and Respiratory Medicine (3.5k citations), Immunology (1.3k citations), Cancer Research (755 citations) and Molecular Biology (1.9k citations). Michael Smylie has collaborated with scholars based in Canada, United States and Italy. Frequent co-authors include Frances A. Shepherd, Lesley Seymour, Andrea Bezjak, Vera Hirsh, B. Findlay, Tudor–Eliade Ciuleanu, P. Santabárbara, Renato Martins, Eng Huat Tan and D. Johnston. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Radiotherapy and Oncology, Journal of Cutaneous Medicine and Surgery and European Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact